<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-047591</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Tumoral response factors after radiofrequency ablation of hepatocellular carcinoma in cirrhotic liver</dc:title>
<dc:description xml:lang="en">Objective: hepatocellular carcinoma (HCC) ablation by radiofrequency(RFA) is a novel technique with a great variety ofmethods whose efficacy and predictive factors have not beencompletely studied. Some of the main predictive factors in thistype of treatment are analyzed in the present study.Patients and methods: ninety-three patients with hepatocellularcarcinoma over cirrhosis, and with no indication for surgicalresection were treated by RFA. Two different types of electrodeswere used for RFA (refrigerated-&#147;Cool-Tip&#148; and perfusion withsaline solution, the approach was percutaneous, by laparoscopyor laparotomy.Results: overall survival at 1, 2 and 3 years was 88, 81, and76%, with a free-disease survival (FDS) of 66, 31 and 17%, respectively.For tumors less than 3 cm, FDS at 1,2 and 3 years was74, 44 and 30%, while for more than 3 cm in size FDS was 55,12 and 0% (p = 0.02). FDS for HCC with one nodule was 70, 36and 22%, and for more than one nodule it decreased to 50, 17and 0% at 1, 2 and 3 years, respectively (p = 0.07). Surprisingly,the method employed for RFA has a main influence in FDS, with0% at 3 years for perfusion electrodes and 26% for cool-tip electrodesat the same period.Conclusions: in this series, overall survival at three years wasrelatively high; however, tumoral size, number of nodules andRFS method were independent variables associated with diseasefreesurvival</dc:description>
<dc:creator>Muro de la Fuente, A</dc:creator>
<dc:creator>Prieto Martín, M</dc:creator>
<dc:creator>Martín Baena, D</dc:creator>
<dc:creator>Calleja Kempin, J</dc:creator>
<dc:creator>Clemente Ricote, G</dc:creator>
<dc:creator>Santos Castro, L</dc:creator>
<dc:creator>Matilla Peña, A</dc:creator>
<dc:creator>Bañares Cañizares, R</dc:creator>
<dc:creator>Colón Rodríguez, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: la ablación por radiofrecuencia del hepatocarcinoma(ARF) es una técnica de reciente adquisición, cuya eficacia yfactores predictivos no han sido suficientemente evaluados. Elpresente estudio fue diseñado para este análisis.Pacientes y métodos: se han tratado 93 pacientes con hepatocarcinomasobre hígado cirrótico sin criterios de resección nide trasplante hepático. El tratamiento se realizó mediante abordajepercutáneo, laparoscópico o mediante laparotomía con dos tiposde electrodos de radiofrecuencia, electrodo refrigerado y deperfusión respectivamente.Resultados: la supervivencia global a los 1, 2 y 3 años fue del88, 81 y 76%, con una supervivencia-libre de enfermedad (SLE)de 66, 31 y 17% respectivamente. El análisis multivariante demostrótres variables predictivas independientes: tamaño tumoral( 3 cm; SLE a 1,2 y 3 años de 74, 44 y 30%,frente a 55, 12 y 0%; HR= 2,02; IC 95% 1,10-3,70; p = 0,02),número de nódulos (uno frente a más de uno; SLE a 1,2 y 3 añosde 70, 36 y 22, frente a 50, 17 y 0%; HR= 1,92 IC 95% 0,95-3,93; p = 0,07) y tipo de electrodo (refrigerado frente a perfusión;SLE 80, 43 y 26% a 1, 2 y 3 años frente a 49, 12 y 0%;HR = 2,06; IC 95% 1,12-3,79; p = 0,02).Conclusiones: a pesar de que la ARF proporciona una supervivenciaglobal aceptable, la SLE es notablemente inferior. El tamañodel tumor, el número de nódulos y el tipo de electrodo deARF fueron variables independientes asociadas a la SLE</dc:description>
<dc:source>Rev Esp Enferm Dig;97(10): 688-698, oct. 2005. tab, graf</dc:source>
<dc:identifier>ibc-047591</dc:identifier>
<dc:title xml:lang="es">Factores de respuesta tumoral tras ablación mediante radiofrecuencia del carcinoma hepatocelular sobre cirrosis</dc:title>
<dc:subject>^d24890</dc:subject>
<dc:subject>^d30797</dc:subject>
<dc:subject>^d8287^s22067</dc:subject>
<dc:subject>^d8287^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d31855^s22067</dc:subject>
<dc:subject>^d31855^s22012</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d8276^s22067</dc:subject>
<dc:subject>^d8276^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>200510</dc:date>
</metadata>
</record>
</ibecs-document>
